Diabetes – Heveren-Healthcare https://heveren.com Trusted pharmaceutical solutions for a healthier tomorrow Sun, 06 Apr 2025 07:49:49 +0000 en-US hourly 1 https://heveren.com/wp-content/uploads/2022/06/cropped-theveren-logo-32x32.png Diabetes – Heveren-Healthcare https://heveren.com 32 32 VALHOK M https://heveren.com/product/valhok-m/ Sun, 06 Apr 2025 07:48:09 +0000 https://heveren.com/?post_type=product&p=1242 Indication : For the treatment of Type-2 Diabetes Mellitus.

Type 2 Diabetes mellitus a chronic condition that affects the way the body processes blood sugar.

MOA : Vildagliptin Inhibits dipeptidyl peptidase-4 (DPP-4), increasing incretin hormones (GLP-1 and GIP), which stimulate insulin release and decrease glucagon levels. Metformin activates AMPK and reduce hepatic glucose levels.

]]> VALHOK https://heveren.com/product/valhok/ Sun, 06 Apr 2025 07:43:09 +0000 https://heveren.com/?post_type=product&p=1235 Indication : For the treatment of Type-2 Diabetes Mellitus.

Type 2 Diabetes mellitus a chronic condition that affects the way the body processes blood sugar.

MOA : It Inhibits dipeptidyl peptidase-4 (DPP-4), increasing incretin hormones (GLP-1 and GIP-2), which stimulate insulin release and decrease glucagon levels.

]]> GLIEVER MV https://heveren.com/product/gliever-mv/ Sun, 06 Apr 2025 07:38:23 +0000 https://heveren.com/?post_type=product&p=1232 Indication : For the treatment of Type-2 Diabetes Mellitus.

Type 2 Diabetes mellitus a chronic condition that affects the way the body processes blood sugar.

MOA : Glimepiride stimulates insulin release from pancreatic beta cells by closing ATPsensitive potassium channels. Voglibose acts as an alpha-glucosidase inhibitor, used to treat type 2 diabetes by delaying carbohydrate digestion and absorption, thereby reducing postprandial blood glucose peaks. Metformin activates AMPK and reduce hepatic glucose levels.

]]> GLIEVER M https://heveren.com/product/gliever-m/ Sun, 06 Apr 2025 07:35:26 +0000 https://heveren.com/?post_type=product&p=1224 Indication : For the treatment of Type-2 Diabetes Mellitus.

Type 2 Diabetes mellitus a chronic condition that affects the way the body processes blood sugar.

MOA : Glimepiride stimulates insulin release from pancreatic beta cells by closing ATPsensitive potassium channels. Metformin activates AMPK and reduce hepatic glucose levels

]]> VOGEVER M https://heveren.com/product/vogever-m/ Sun, 06 Apr 2025 07:28:49 +0000 https://heveren.com/?post_type=product&p=1220 Indication : For the treatment of Type-2 Diabetes Mellitus.

Type 2 Diabetes mellitus a chronic condition that affects the way the body processes blood sugar.

MOA : Voglibose acts as an alpha-glucosidase inhibitor, used to treat type 2 diabetes by delaying carbohydrate digestion and absorption, thereby reducing postprandial blood glucose peaks. Metformin activates AMPK and reduce hepatic glucose levels.

]]> VOGEVER https://heveren.com/product/vogever/ Sun, 06 Apr 2025 07:23:45 +0000 https://heveren.com/?post_type=product&p=1211 Indication : For the treatment of Type-2 Diabetes Mellitus.

Type 2 Diabetes mellitus a chronic condition that affects the way the body processes blood sugar.

MOA : Voglibose acts as an alpha – glucosidase inhibitor, used to treat type 2 diabetes by delaying carbohydrate digestion and absorption, thereby reducing postprandial blood glucose peaks.

]]>